Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D05CEO
|
||||
Former ID |
DNCL003320
|
||||
Drug Name |
Brodalumab
|
||||
Synonyms |
AMG 827
|
||||
Drug Type |
Monoclonal antibody
|
||||
Company |
Valeant Luxembourg
|
||||
Target and Pathway | |||||
Target(s) | Interleukin-17 | Target Info | Modulator | [556264] | |
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Interleukin signaling pathway | ||||
Pathway Interaction Database | IL27-mediated signaling events | ||||
IL23-mediated signaling events | |||||
References | |||||
Ref 524588 | ClinicalTrials.gov (NCT02029495) Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis. U.S. National Institutes of Health. | ||||
Ref 542542 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7540). | ||||
Ref 550248 | Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis | ||||
Ref 889446 | Drugs@FDA (Edaravone) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.